Sa1371 REAL-WORLD EFFICACY OF SECOND-LINE THERAPIES FOR HELICOBACTER PYLORI: A POPULATION-BASED STUDY Read More →
Sa1370 INCIDENCE AND PREDICTORS OF C. DIFFICILE INFECTION AFTER HELICOBACTER PYLORI TREATMENT IN A LARGE, COMMUNITY-BASED U.S. POPULATION Read More →
Sa1361 CROSS-SECTIONAL ANALYSIS OF REAL-WORLD DATA IN GASTRIC CANCER SCREENING BASED ON HELICOBACTER PYLORI INFECTION HISTORY IN PRIVATE HEALTH CHECK-UPS Read More →
Sa1368 SYNERGISTIC EFFECTS OF NOVEL PENICILLIN-BINDING PROTEIN 1A AMINO ACID SUBSTITUTIONS CONTRIBUTE TO HIGH-LEVEL AMOXICILLIN RESISTANCE OF HELICOBACTER PYLORI Read More →
Sa1367 BOTH 14-DAY VONOPRAZAN TRIPLE THERAPY AND 14-DAY RABEPRAZOLE REVERSE HYBRID THERAPY ARE SUPERIOR TO 14-DAY VONOPRAZAN HIGH-DOSE DUAL THERAPY FOR THE FIRST-LINE ANTI-H. PYLORI TREATMENT IN POPULATION WITH HIGH RATES OF ANTIBIOTIC RESISTANCE Read More →
Sa1366 ASSESSING GENOTYPIC RESISTANCE OF CLARITHROMYCIN AND LEVOFLOXACIN IN PATIENTS WITH H. PYLORI INFECTION: COMPARATIVE ANALYSIS OF GASTRIC MUCOSA, GASTRIC JUICE, AND FECAL SAMPLES Read More →
Sa1365 AGREEMENT BETWEEN STOMACH BIOPSY CULTURE AND STOOL NEXT-GENERATION SEQUENCING FOR DETERMINING HELICOBACTER PYLORI ANTIBIOTIC SUSCEPTIBILITY PROFILES IN A SCREENING PREDOMINANTLY HISPANIC U.S. POPULATION Read More →
Sa1364 TEN-VERSUS FOURTEEN-DAY VONOPRAZAN AND HIGH-DOSE AMOXICILLIN DUAL-THERAPY FOR HELICOBACTER PYLORI ERADICATION: A PROSPECTIVE, OPEN-LABELED, MULTICENTER, RANDOMIZED NONINFERIORITY STUDY Read More →
Sa1363 HELICOBACTER PYLORI TREATMENT, FOLLOW-UP AND OUTCOMES IN A PREDOMINANTLY HISPANIC POPULATION IN THE UNITED STATES Read More →
Sa1362 HELICOBACTER PYLORI DETECTION AMONG PATIENTS WITH DYSPEPSIA UNDERGOING ESOPHAGOGASTRODUODENOSCOPY ON PROTON PUMP INHIBITORS -UNPACKING THE GAP BETWEEN GUIDELINES AND CLINICAL PRACTICE. Read More →
Sa1377 SEVEN-DAY VONOPRAZAN-BASED TRIPLE THERAPY AS FIRST-LINE HELICOBACTER PYLORI TREATMENT IN COMPARISON WITH EXTENDED SEQUENTIAL THERAPY: A RANDOMIZED CONTROLLED TRIAL Read More →
653 VONOPRAZAN-BASED DUAL AND TRIPLE THERAPY VERSUS BISMUTHBASED QUADRUPLE THERAPY AS FIRST-LINE THERAPY FOR HELICOBACTER PYLORI INFECTION IN CHINA: A THREE-ARMED, RANDOMIZED CLINICAL TRIAL Read More →
572 REDUCTION OF DISPARITIES IN H. PYLORI TREATMENT AND ERADICATION FOLLOWING IMPLEMENTATION OF A MULTIDISCIPLINARY TREATMENT PROGRAM. Read More →
Sa1378 HELICOBACTER PYLORI ERADICATION TREATMENT REGIMEN SELECTION FOR PATIENTS WITH DECREASED RENAL FUNCTION: A SYSTEMATIC REVIEW Read More →
Sa1386 GENETIC VARIANTS OF HELICOBATER PYLORI THAT ARE RESISTANT TO FURAZOLIDONE AND RIFAMPICIN IN COLOMBIA Read More →
Sa1389 EFFICACY OF NOVEL POTASSIUM-COMPETITIVE ACID BLOCKERS, VONOPRAZAN AND FEXUPRAZAN, VERSUS CONVENTIONAL PROTON PUMP INHIBITOR-BASED TRIPLE THERAPY FOR ERADICATION OF HELICOBACTER PYLORI, A RETROSPECTIVE COHORT STUDY IN A PHILIPPINE TERTIARY HOSPITAL Read More →
